243 related articles for article (PubMed ID: 31444238)
1. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
[TBL] [Abstract][Full Text] [Related]
2. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
4. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Khout H; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2018 Dec; 119(12):1518-1526. PubMed ID: 30410060
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
6. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
[TBL] [Abstract][Full Text] [Related]
7. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
Miligy IM; Toss MS; Gorringe KL; Ellis IO; Green AR; Rakha EA
Pathobiology; 2022; 89(6):382-392. PubMed ID: 35533650
[TBL] [Abstract][Full Text] [Related]
8. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Gorringe KL; Aleskandarany MA; Alkawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Rakha EA
Mod Pathol; 2019 Oct; 32(10):1460-1472. PubMed ID: 31175327
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
Al-Kawaz A; Miligy IM; Toss MS; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Jul; 188(1):53-63. PubMed ID: 34117958
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
12. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
16. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
[TBL] [Abstract][Full Text] [Related]
17. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
[TBL] [Abstract][Full Text] [Related]
18. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
19. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
20. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
Woo JW; Choi HY; Kim M; Chung YR; Park SY
Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
